A Phase I, Open Label, Single Dose, Two Parts Study in Male and Female Healthy Subjects to Assess the Safety and Pharmacokinetics of Fosnetupitant 235 mg Administered as IV Bolus and of Derived Netupitant and Netupitant Metabolites
Latest Information Update: 12 May 2025
At a glance
- Drugs Fosnetupitant (Primary) ; Netupitant/palonosetron
- Indications Chemotherapy-induced nausea and vomiting
- Focus Adverse reactions
- Sponsors Helsinn Healthcare SA
Most Recent Events
- 28 Feb 2025 New trial record